In VivoMollie Leoni’s path to becoming chief medical officer was anything but conventional. “I was going to be a ballet dancer,” she recalled with a smile. But as reality set in, when she “finally realized”
In VivoIncluded for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list
In VivoPharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com
Scrip“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru